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Abstract
Introduction—Shingles (herpes zoster) causes substantial morbidity, especially among older 
adults. The shingles vaccine has been recommended for people aged ≥60 years since 2006. This 
study assessed recent shingles vaccination at national and state levels among adults aged ≥60 
years.
Methods—The 2014 Behavioral Risk Factor Surveillance System data were analyzed in 2015 to 
assess shingles vaccination coverage among adults aged ≥60 years at national and state levels. 
Multivariable logistic regression and predictive marginal models identified factors independently 
associated with vaccination.
Results—Shingles vaccination coverage among adults aged ≥60 years was 31.8% (95% 
CI=31.4%, 32.2%). Among states, shingles vaccination coverage ranged from 17.8% (95% 
CI=15.8%, 20.0%) in Mississippi to 46.6% (95% CI=44.3%, 48.8%) in Vermont, with a median of 
33.3%. Coverage was <25% in four states and >40% in nine states. For all states, coverage was 
significantly higher among non-Hispanic whites compared with non-white races except for 
Oregon, with coverage differences ranging from −33.2% in the District of Columbia to 0.9% in 
Oregon and a median of −16.0%. Characteristics independently associated with vaccination were 
age, race/ethnicity, sex, education, employment status, household income, region, perceived health 
status, health insurance status, personal healthcare provider, routine checkup status, and whether 
reporting that cost was a barrier to seeing a doctor.
Conclusions—Coverage varied dramatically by state. State-level comparisons may aid in 
designing tailored intervention programs through sharing of best practices. Strategies are needed 
to mitigate financial barriers for both provider and patients, improve awareness, and increase 
provider recommendation of the vaccine.
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Introduction
Herpes zoster, or shingles, is caused by reactivation of the varicella zoster virus. The risk of 
shingles increases with age and is approximately three times higher among adults aged ≥65 
years compared with those aged <65 years.1–4 More than half of all people diagnosed with 
shingles each year are aged ≥50 years.4 In the U.S., more than 99% of adults have serologic 
evidence of varicella zoster virus infection and are susceptible to shingles,5 with an 
estimated individual lifetime risk of approximately 30%.4 Ten to 30 percent of people 
experiencing shingles develop postherpetic neuralgia (PHN), a debilitating neuropathic pain 
syndrome that can last months or even years and is often refractory to treatment, with the 
risk of PHN increasing with age.3,4,6 Approximately 1 million new cases of shingles are 
diagnosed annually.4–11 The incidence rate of shingles ranges between three and five per 
1,000 person-years in prior studies in the U.S. and other countries, depending on the studied 
population and immunocompetency of subjects.4–11 Shingles results in an estimated $566 
million in total healthcare costs.12 Additionally, shingles causes indirect cost with an average 
loss exceeding 129 hours of work per episode.7,13 Much of the burden of shingles and PHN 
is, however, borne by patients as reduced quality of life because of associated pain and 
suffering.3,6
The zoster vaccine, Zostavax®, was licensed in 2006 by the U.S. Food and Drug 
Administration for prevention of shingles, as well as prevention and treatment of PHN. The 
Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination 
of all people aged ≥60 years with one dose of zoster vaccine in October 2006; these 
recommendations were published in May 2008.6,14 Cost effectiveness of Zostavax varies 
depending on patients' age and is more cost effective for patients aged 60–70 years but is not 
as cost effective for patients aged >80 years.15,16
This study used data from the 2014 Behavioral Risk Factor Surveillance System (BRFSS) to 
assess recent national and state-specific shingles vaccination coverage and identify factors 
independently associated with vaccination among adults aged ≥60 years in the U.S. Such 
information may help identify which strategies can help improve vaccination coverage 
among adult populations.
Methods
The 2014 BRFSS data were analyzed in 2015. BRFSS is a continuous, population-based 
telephone survey coordinated by state health departments in collaboration with the Centers 
for Disease Control and Prevention (CDC). BRFSS collects information from non-
institutionalized adults aged ≥18 years. BRFSS is conducted monthly in all 50 states and the 
District of Columbia (DC). The objective of BRFSS is to collect uniform, state-specific data 
on self-reported preventive health practices and risk behaviors that are linked to chronic 
diseases, injuries, and preventable infectious diseases. Individuals are selected randomly 
using a multistage cluster design. Data are weighted by age, sex, and in some states, race/
ethnicity, to reflect each area's estimated adult population.17 Beginning in 2011, surveys 
included landline and cellular telephone households and used a new method for weighting.18
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To determine shingles vaccination status in all states, a question on shingles vaccination was 
added to the 2014 BRFSS core questionnaire as part of a 3-year rotation with questions to 
assess tetanus diphtheria and tetanus, diphtheria, and acellular pertussis vaccination 
coverage (2013) and in place of influenza vaccination (2015). Respondents were asked, 
Have you ever had the shingles or zoster vaccine? Respondents who answered yes were 
considered vaccinated. For 2014 BRFSS, the median American Association of Public 
Opinion Research (RR4) landline, cellular phone, and combined response rates were 48.7% 
(range, 26.7%–61.6%); 40.5% (range, 22.2%–60.0%); and 25.1% (range, 25.1%–60.1%), 
respectively.19
SUDAAN, version 11.0.1, was used to calculate point estimates and 95% CIs.20 All analyses 
were weighted to reflect the age, sex, and race/ethnicity of the U.S. non-institutionalized 
civilian population. All tests were two-tailed with the significance level set at α < 0.05. 
State-specific shingles vaccination coverage was also evaluated. Multivariable logistic 
regression models were conducted (all variables selected were included in the model) and 
predictive marginal models20 were used to generate adjusted prevalence and adjusted 
prevalence differences and to identify variables independently associated with shingles 
vaccination among adults aged ≥60 years.
Results
A total of 208,505 adults aged ≥60 years were included in the 2014 BRFSS. Of those, 1.7% 
(3,486) who answered don't know or declined to the question were excluded from the 
assessment of shingles vaccination. Demographic characteristics of the study population are 
provided in Table 1. The majority of participants were aged 60–74 years (70.0%); female 
(54.8%); white (77.5%); married or a member of an unmarried couple (59.1%); had some 
college (or technical school) education or higher (54.5%); were not in workforce (72.9%); 
had household income <$50,000 (61.5%); living in South or West (59.7%); perceived their 
health status as being excellent/very good or good (74.7%); had medical insurance (96.1%); 
had a personal healthcare provider (92.9%); had a routine checkup last year (85.6%); and did 
not report that cost prevented them from seeing a doctor during the past 12 months (93.0%).
In the univariate analysis, shingles vaccination coverage was 31.8% (95% CI=31.4%, 
32.2%) among adults aged ≥60 years. Shingles vaccination coverage was significantly 
higher among adults aged 65–74 years (35.9%); 75–79 years (37.7%); and ≥80 years 
(34.3%) compared with adults aged 60–64 years (22.0%) (Table 2). Coverage was 5.9% 
among adults aged 50–59 years (data not shown). Shingles vaccination coverage among 
adults aged ≥60 years was significantly lower among non-Hispanic blacks (16.0%); 
Hispanics (16.7%); and American Indians and Alaska Natives (27.2%) compared with non-
Hispanic whites (35.4%), but was not significantly lower for Asians (30.2%) compared with 
non-Hispanic whites. Shingles vaccination coverage was significantly higher among adults 
who were female, reported having higher education, reported higher income, were not in 
workforce, were living in the Midwest or West of the U.S., perceived their health status as 
being excellent/very good or good, reported having medical insurance, reported having a 
personal healthcare provider, reported having a routine checkup in the previous year, and did 
not report that cost prevented them from seeing a doctor (Table 2). Shingles vaccination 
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coverage was significantly lower among those who reported being widowed, divorced, 
separated, or never married; being unemployed; or living in the South of the U.S. (Table 2).
In multivariable analysis, characteristics independently associated with an increased 
likelihood of shingles vaccination among adults aged ≥60 years were older age; being 
female; higher education; not being in the workforce, household income ≥$20,000; living in 
the Midwest, West, or South of the U.S.; perceived health status being excellent/very good, 
good, or fair; having health insurance; having a personal healthcare provider; having a 
routine checkup in the previous year; and not reporting that cost prevented them from seeing 
a doctor during the past 12 months (Table 3). African American and Asian race and Hispanic 
ethnicity were independently associated with a decreased likelihood of shingles vaccination 
(Table 3).
Among all 50 states and DC, shingles vaccination coverage among adults aged ≥60 years 
varied widely, ranging from 17.8% in Mississippi to 46.6% in Vermont, with a median of 
33.3%. Overall coverage ranged from 25.1% in DHHS Region 2 to 43.2% in Region 10. 
Shingles vaccination coverage among adults aged ≥60 years was <25% in four states 
(Mississippi, New Jersey, Louisiana, and Alabama) and >40% in nine states (Vermont, 
Oregon, Washington, Minnesota, North Dakota, Colorado, Maine, South Dakota, and 
Nebraska) (Table 4).
Shingles vaccination coverage among non-Hispanic white adults aged ≥60 years ranged 
from 22.3% in Mississippi to 52.8% in DC, with a median of 35.7%. Coverage was <25% in 
two states (Mississippi and New Jersey); >45% in four states (DC, Vermont, Washington, 
Minnesota); and >30% in 34 states (Table 4). Shingles vaccination coverage among non-
white adults aged ≥60 years ranged from 6.3% in Mississippi to 45.6% in Oregon, with a 
median of 20.3%. Coverage among non-white adults aged ≥60 years was <15% in nine 
states (Illinois, Missouri, Georgia, Florida, New York, South Carolina, Alabama, Louisiana, 
and Mississippi) and >30% in eight states (Oregon, Hawaii, North Dakota, New Hampshire, 
Washington, Colorado, Minnesota, and Wyoming) (Table 4). For all states, shingles 
coverage was significantly higher among non-Hispanic whites compared with non-white 
races except for Oregon, with coverage differences ranging from −33.2% in DC to 0.9% in 
Oregon and a median of −16.0%.
Discussion
Shingles vaccination coverage exceeded 30% in 34 states, indicating that a majority of states 
reached the Healthy People 2020 target of 30% coverage among adults aged ≥60 years,21 
although a large majority of Americans have not received the shingles vaccine. Although 
BRFSS is a population-based survey designed to produce representative state-level 
assessments, data are routinely aggregated for national estimation of certain behavior and 
health outcomes. Comparing the shingles vaccination coverage estimate in this study derived 
by aggregating 2014 BRFSS state-level data (31.8%) to the estimate (27.9%) from the 
nationally representative 2014 National Health Interview Survey22 revealed a 3.9–
percentage point difference. The difference in coverage estimates between these two surveys 
might be due to differences in survey design and administration; operations (in-person 
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survey for the National Health Interview Survey, and telephone survey for BRFSS), and 
weighting procedures.18,19,22,23
A 2007 U.S. study showed that soon after shingles vaccine was licensed and recommended 
for people aged ≥60 years in 2006, vaccination coverage in this target population was 1.9%.
24
 Shingles vaccination coverage has steadily increased since vaccine licensure.22,24,25 
Shingles vaccination coverage among adults aged ≥60 years reached 31.8% in 2014, which 
was 8 years after the recommendation. Shingles vaccination coverage could be compared to 
pneumococcal polysaccharide vaccination, another vaccine that was recommended to senior 
adults in 1983. Pneumococcal vaccine coverage increased to 21%–24% among adults aged 
≥65 years by 1991–1992 (8 years after recommendation); coverage then further increased to 
58%–69% in 2014.22,26,27 To increase vaccination coverage among senior adults, healthcare 
providers are encouraged to include vaccination status assessment, recommendation and 
offer of vaccination, or referral if vaccines that are needed are not available, as a routine in 
their practices.28
Several factors might have contributed to slower shingles vaccination uptake. First, shortages 
of herpes zoster vaccine and a resulting lack of vaccine promotion likely contributed to low 
uptake during the first years after vaccine licensure. Although these shortages have been 
resolved, other barriers persist, particularly high vaccine cost for providers and challenges to 
stocking the vaccine (stringent storage and handling requirements) and receiving 
reimbursement for vaccination services.22,25,29 Second, coverage for shingles vaccine under 
Medicare Part D results in billing challenges for providers (except pharmacists) and out-of-
pocket expenses for some Medicare Part D beneficiaries (high co-pays; median, 
approximately $70–$80), and additionally, not every Medicare recipient has elected to 
participate in Part D.22,29 Third, physicians were not strongly promoting shingles 
vaccination to their patients. One study showed that only 41% of providers strongly 
recommended shingles vaccine to their patients compared with more than 90% who strongly 
recommended influenza and pneumococcal vaccination.29 Fourth, awareness of shingles 
vaccine among patients was low,24 particularly if providers were not aggressively promoting 
the shingles vaccination. One study reported that in 2008, 2 years after vaccine licensure, 
only 27% of adults aged ≥60 years were aware of the shingles vaccine.24 In 2015, 73.4% of 
the target population reported awareness of the shingles vaccine (CDC, Immunization 
Services Division, unpublished data), indicating that by the end of 2014, 8 years after 
shingles vaccine was recommended, the large majority of adults were aware of the shingles 
vaccine but approximately one fourth of adults aged ≥60 years did not know about the 
vaccine despite a major sustained direct-to-consumer TV advertising campaign sponsored by 
the manufacturer. Compared with shingles vaccine, in 2015, a total of 86.6% of adults ≥65 
years reported awareness of the pneumococcal vaccine. Finally, most people without 
medical insurance were confronted with substantial financial barriers, as the high retail price 
of shingles vaccine would need to be paid out of pocket. For those with commercial 
insurance, out-of-pocket costs are less clear. For adults aged ≥60 years with non-
grandfathered private health insurance plans, shingles vaccine is available with no out-of-
pocket costs because of provisions of the Affordable Care Act.22,29 Strategies are needed to 
mitigate financial barriers, improve awareness, and increase provider recommendation of the 
vaccine.
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Because shingles vaccination information was newly added to the 2014 BRFSS core 
questionnaire, this is the first study to assess state-specific shingles vaccination coverage 
among adult populations across the entire U.S. The shingles vaccination question will be 
added to the 2017 BRFSS core questionnaire as part of its 3-year rotation with two other 
questions. Results from this study provide a baseline for state-level shingles coverage in the 
U.S. Substantial differences in coverage among states were observed for shingles 
vaccination. Variation in state coverage could be due to differing medical care delivery 
infrastructure, population composition, socioeconomic factors, state laws, effectiveness of 
state and local immunization programs among states, and other factors.23,30–33 Wide 
variation in vaccination coverage among states has also been observed for influenza and 
pneumococcal vaccination among older adults in a similar pattern as shingles vaccination,
27,34
 possibly because of comparable factors. State-specific influenza vaccination coverage 
in the 2014–2015 season among adults aged ≥65 years ranged from 57.2% to 76.8%, and 
pneumococcal vaccination coverage in 2014 among adults aged ≥65 years ranged from 
60.5% to 76.1%.27,34 Because there is a wide variation in vaccination of elderly adults 
across states, future research on state-specific factors associated with vaccination could 
prompt actions, policies, and programs in other states to increase vaccination uptake. State 
immunization programs are encouraged to engage providers and other stakeholders to 
implement interventions shown to be effective in increasing vaccination among adults.35
Of note, this analysis showed that shingles vaccination coverage was 5.9% among adults 
aged 50–59 years for whom the vaccine is licensed by the U.S. Food and Drug 
Administration but not recommended by ACIP.36 The lower coverage among adults aged 
50–59 years compared with other age groups may be partially due to lack of official 
recommendation of the vaccine by ACIP. Additional information is needed on long-term 
protection afforded by herpes zoster vaccine in this age group and cost effectiveness of 
vaccination at younger versus older ages to assist future decisions on recommending 
shingles vaccination in younger groups.
Racial and ethnic disparities in vaccination rates have been reported for adult vaccines, 
including those for influenza, pneumococcal, tetanus, shingles, human papillomavirus, and 
hepatitis B vaccines.37–40 The present findings are consistent with those reported previously 
from a nationally representative survey.40 In this study, racial and ethnic disparities in 
shingles vaccination coverage also were observed in most states. In addition, although 
shingles vaccination is publically funded in the United Kingdom with an aggressive 
vaccination program, disparities in shingles vaccine uptake between white and racial and 
ethnic minority populations also exist.41 These disparities may reflect differences in general 
quality of care, community differences in attitudes toward vaccination and preventive care in 
general, differences in concerns about vaccination, including safety, or differences in doctor–
patient interactions.37–40 To improve coverage and eliminate disparities in adult vaccination, 
greater implementation of evidence-based interventions are needed, including the use of 
reminder/recall systems, standing orders for vaccination, regular assessments of vaccination 
coverage levels among provider practices, vaccination registries, and improving public and 
provider awareness of the importance of vaccinations for adults.35,37–42
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Women were more likely to receive shingles vaccination than men. This may partly be 
because women are more aware of shingles and shingles vaccine or generally see healthcare 
providers and use preventive service more frequently than men.24,43,44 Educational levels 
were also independently positively associated with shingles vaccination. People with less 
education may experience more barriers to receiving care perhaps because of lack of 
knowledge regarding preventive services45,46 in general or regarding shingles vaccine 
specifically.24,29 Additionally, having health insurance, a personal healthcare provider, and a 
routine checkup in the previous year were independently associated with higher shingles 
vaccination coverage. These findings are consistent with previous reports.37–39,47–50
Limitations
The findings in this report are subject to at least two limitations. First, vaccination coverage 
was self-reported and therefore might be subject to recall bias. However, adult self-reported 
vaccination status for shingles and other vaccines has been shown to be sensitive and 
specific.51 In addition, the authors were not able to determine age-specific vaccine uptake, as 
BRFSS respondents were asked whether they had ever received the vaccine, and time of 
vaccination was not collected. Thus, for instance, a person aged 80 years who reported 
receipt of shingles vaccine might have been vaccinated soon after vaccine licensure in 2006, 
when they were aged 72 years.
Conclusions
Use of zoster vaccine can significantly reduce morbidity caused by shingles among adults 
aged ≥60 years. CDC is actively monitoring post-marketing data on duration of vaccine 
protection in adults vaccinated at age ≥60 years. As additional data become available, ACIP 
will re-evaluate the need for a booster dose to maintain protection against herpes zoster and 
its complications.36 If all eligible adults aged ≥60 years are vaccinated in accordance with 
ACIP recommendations, the vaccine could prevent a quarter of a million cases of shingles 
annually.52,53 However, this study found that 8 years after shingles vaccine became 
available, vaccination coverage was only 31.8%, and coverage varied by states. Increased 
state and national efforts using comprehensive strategies shown to be effective are needed to 
improve shingles vaccination coverage levels. Financial barriers to providers (vaccine 
purchase and compensation) and patients (out-of-pocket expenses) play a role in shingles 
vaccine uptake and should be mitigated. Pharmacies are playing an important role in 
shingles vaccination, partially because they can be reimbursed by Medicare Part D benefits.
29,54
 Evidence suggests some success of pharmacy interventions to remove barriers to 
shingles vaccination and increase shingles vaccination coverage.55–58 Because of Part D 
reimbursement structure, convenience of pharmacy locations and hours, and pharmacists' 
established roles as vaccination providers, pharmacists are in an optimal position to identify, 
educate, and vaccinate eligible patients against shingles.29,54–58 Other comprehensive 
strategies for improving shingles vaccination uptake include use of reminder/recall systems; 
educational campaigns; use of standing orders; linking delivery of shingles vaccine to 
delivery of other indicated adult vaccines (e.g., influenza); and routinely assessing patients' 
vaccination status.6,35,59–61
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Table 1
Sample Characteristics Among Adults Aged ≥60 years, U.S., BRFSS 2014
Characteristic
All adults
Sample (n) Weighted %
Total 208,505 100.0
Age (years)
 60–64 51,850 29.3
 65–74 89,423 40.7
 75–79 28,837 13.9
 ≥80 38,395 16.1
Sex
 Male 81,386 45.2
 Female 127,119 54.8
Race/ethnicity
 White, non-Hispanic 176,277 77.5
 Black, non-Hispanic 13,506 9.7
 Hispanic 6,717 7.9
 Asian, non-Hispanic 2,135 2.7
 American Indian/Alaska Native, non-Hispanic 2,320 0.8
 Other 4,025 1.4
Marital status
 Married or unmarried couple 108,322 59.1
 Divorced, widowed, or separated 87,366 36.2
 Never married 11,408 4.7
Education level
 Less than high school 17,757 15.2
 High school graduate 63,552 30.3
 Some college or technical school 54,998 29.7
 College graduate or higher education 70,688 24.8
Employment
 Employed 50,179 24.5
 Unemployed 4,099 2.6
 Not in workforce 152,259 72.9
Income ($)
 <20,000 33,848 21.1
 20,000–49,999 71,840 40.4
 50,000–74,999 26,891 15.5
 ≥75,000 37,788 23.0
Region
 Northeast 37,378 18.5
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Characteristic
All adults
Sample (n) Weighted %
 Midwest 57,096 21.8
 South 64,449 37.6
 West 49,582 22.1
Perceived health
 Excellent or very good 92,772 42.2
 Good 67,071 32.5
 Fair 33,259 17.5
 Poor 14,431 7.8
Have medical insurance
 Yes 202,433 96.1
 No 5,552 3.9
Have personal healthcare provider
 Yes 193,696 92.9
 No 13,979 7.1
Time since last routine checkup
 <1 year 173,335 85.6
 ≥1 year 31,257 14.4
Unable to see doctor due to cost
 Yes 11,878 7.0
 No 196,036 93
BRFSS, Behavioral Risk Factor Surveillance System.
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Table 2
Shingles Vaccination Coverage Among Adults Aged ≥60 Years by Selected Demographic 
and Access-to-Care Characteristics—U.S., BRFSS 2014
Characteristic Shingles vaccination coverage, % (95% CI) Difference,a % (95% CI)
Total 31.8 (31.4, 32.2) NA
Age (years)
 60–64b 22.0 (21.3, 22.7) ref
 65–74 35.9 (35.3, 36.6)* 14.0 (13.0, 14.9)
 75–79 37.7 (36.6, 38.9)* 15.8 (14.4, 17.1)
 ≥80 34.3 (33.3, 35.2)* 12.3 (11.1, 13.5)
Sex
 Maleb 30.6 (29.9, 31.2) ref
 Female 32.9 (32.3, 33.4)* 2.3 (1.5, 3.1)
Race/ethnicity
 White, non-Hispanicb 35.4 (35.0, 35.8) ref
 Black, non-Hispanic 16.0 (14.7, 17.4)* −19.4 (−20.8, −18.0)
 Hispanic 16.7 (14.9, 18.6)* −18.7 (−20.6, −16.8)
 Asian, non-Hispanic 30.2 (25.2, 35.8) −5.1 (−10.4, 0.2)
 American Indian/Alaska Native, non-Hispanic 27.2 (23.6, 31.1)* −8.2 (−12.0, −4.4)
 Other 27.2 (24.2, 30.6)* −8.1 (−11.3, −4.9)
Marital status
 Married or unmarried coupleb 34.3 (33.7, 34.8) ref
 Divorced, widowed, or separated 28.7 (28.1, 29.4)* −5.6 (−6.4, −4.7)
 Never married 25.0 (23.3, 26.7)* −9.3 (−11.1, −7.5)
Education level
 Less than high schoolb 17.9 (16.8, 19.0) ref
 High school graduate 28.5 (27.8, 29.2)* 10.6 (9.3, 11.9)
 Some college or technical school 32.7 (31.9, 33.5)* 14.8 (13.5, 16.2)
 College graduate or higher education 43.0 (42.3, 43.7)* 25.1 (23.8, 26.4)
Employment
 Employedb 26.8 (26.1, 27.6) ref
 Unemployed 17.8 (15.6, 20.3)* −9.0 (−11.5, −6.5)
 Not in workforce 34.0 (33.5, 34.5)* 7.2 (6.3, 8.1)
Income ($)
 <20,000b 18.4 (17.5, 19.3) ref
 20,000–49,999 30.1 (29.5, 30.8)* 11.8 (10.7, 12.8)
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Characteristic Shingles vaccination coverage, % (95% CI) Difference,a % (95% CI)
 50,000–74,999 38.0 (36.9, 39.2)* 19.7 (18.2, 21.1)
 ≥75,000 41.9 (40.9, 42.9)* 23.5 (22.2, 24.8)
Region
 Northeastb 30.3 (29.4, 31.2) ref
 Midwest 33.2 (32.5, 33.9)* 2.9 (1.8, 4.1)
 South 28.7 (28.1, 29.3)* −1.5 (−2.6, −0.5)
 West 37.4 (36.3, 38.6)* 7.1 (5.7, 8.6)
Perceived health
 Excellent or very good 37.0 (36.4, 37.6)* 17.2 (15.8, 18.6)
 Good 31.8 (31.1, 32.5)* 12.0 (10.5, 13.4)
 Fair 24.6 (23.7, 25.6)* 4.8 (3.2, 6.4)
 Poorb 19.8 (18.6, 21.1) ref
Have medical insurance
 Yes 32.7 (32.3, 33.1)* 23.3 (21.9, 24.8)
 Nob 9.4 (8.1, 10.9) ref
Have personal health care provider
 Yes 33.1 (32.7, 33.5)* 17.4 (15.9, 18.8)
 Nob 15.7 (14.4, 17.1) ref
Time since last routine checkup
 <1 year 34.0 (33.5, 34.4)* 13.6 (12.6, 14.6)
 ≥1 yearb 20.4 (19.5, 21.3) ref
Unable to see doctor due to cost
 Yesb 15.9 (14.6, 17.3) ref
 No 33.0 (32.6, 33.5)* 17.1 (15.7, 18.5)
Note: Boldface indicates statistical significance
*p < 0.05 by t test comparing against reference group).
a
Percentage point difference compared to the reference group.
b
Reference level.
BRFSS, Behavioral Risk Factor Surveillance System.
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Table 3
Multivariable Logistic Regression Analysis of Persons Aged ≥60 Years Who Reported 
Shingles Vaccination, by Selected Demographic and Access-to-Care Characteristics, U.S., 
BRFSS 2014
Characteristic
Adjusted shingles vaccination 
coverage, % (95% CI)
Adjusted prevalence difference (PD), PD 
(95% CI)
Age (years)
 60–64a 24.1 (23.2, 24.9) ref
 65–74 35.0 (34.3, 35.7) 10.9 (9.8, 12.0)*
 75–79 37.7 (36.4, 39.0) 13.7 (12.1, 15.2)*
 ≥80 34.9 (33.8, 36.1) 10.9 (9.4, 12.4)*
Sex
 Malea 30.4 (29.7, 31.0) ref
 Female 33.7 (33.1, 34.3) 3.4 (2.5, 4.3)*
Race/ethnicity
 White, non-Hispanica 34.0 (33.6, 34.5) ref
 Black, non-Hispanic 20.1 (18.3, 21.9) −13.9 (−15.8, −12.1)*
 Hispanic 25.2 (22.6, 27.8) −8.9 (−11.5, −6.2)*
 Asian, non-Hispanic 27.3 (22.5, 32.0) −6.8 (−11.5, −2.0)*
 American Indian/Alaska Native, non-Hispanic 34.0 (29.4, 38.6) −0.1 (−4.7, 4.5)
 Other 30.8 (27.0, 34.7) −3.2 (−7.1, 0.7)
Marital status
 Married or unmarried couplea 32.3 (31.7, 32.9) ref
 Divorced, widowed, or separated 31.9 (31.1, 32.6) −0.5 (−1.5, 0.6)
 Never married 31.7 (29.5, 33.9) −0.6 (−2.9, 1.7)
Education level
 Less than high schoola 25.5 (23.8, 27.2) ref
 High school graduate 29.1 (28.3, 29.9) 3.5 (1.7, 5.4)*
 Some college or technical school 31.9 (31.1, 32.7) 6.3 (4.5, 8.2)*
 College graduate or higher education 38.2 (37.4, 39.0) 12.6 (10.7, 14.6)*
Employment
 Employeda 26.6 (25.7, 27.4) ref
 Unemployed 26.9 (23.6, 30.3) 0.4 (−3.1, 3.8)
 Not in workforce 34.3 (33.8, 34.9) 7.8 (6.7, 8.8)*
Income ($)
 <20,000a 23.7 (22.6, 24.9) ref
 20,000–49,999 30.0 (29.3, 30.7) 6.3 (5.0, 7.6)*
 50,000–74,999 35.9 (34.8, 37.0) 12.2 (10.5, 13.9)*
 ≥75,000 39.1 (38.0, 40.2) 15.4 (13.6, 17.2)*
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Characteristic
Adjusted shingles vaccination 
coverage, % (95% CI)
Adjusted prevalence difference (PD), PD 
(95% CI)
Region
 Northeasta 29.1 (28.2, 30.0) ref
 Midwest 32.7 (31.9, 33.4) 3.6 (2.4, 4.8)*
 South 30.4 (29.7, 31.1) 1.3 (0.2, 2.5)*
 West 37.2 (36.1, 38.4) 8.1 (6.7, 9.6)*
Perceived health
 Excellent or very good 34.3 (33.6, 35.0) 9.0 (7.1, 10.9)*
 Good 32.2 (31.4, 33.0) 6.9 (5.0, 8.8)*
 Fair 28.4 (27.2, 29.5) 3.1 (1.0, 5.1)*
 Poora 25.3 (23.6, 27.0) ref
Have medical insurance
 Yes 32.3 (31.8, 32.8) 8.9 (5.6, 12.3)*
 Noa 23.4 (20.1, 26.7) ref
Have personal healthcare provider
 Yes 32.5 (32.0, 33.0) 7.3 (5.0, 9.6)*
 Noa 25.2 (23.0, 27.5) ref
Time since last routine checkup
 <1 year 33.6 (33.1, 34.1) 10.7 (9.5, 11.9)*
 ≥1 yeara 22.9 (21.8, 24.0) ref
Unable to see doctor due to cost
 Yesa 26.7 (24.6, 28.7) ref
 No 32.4 (31.9, 32.9) 5.8 (3.7, 7.8)*
Note: Boldface indicates statistical significance (p < 0.05 by t test comparing against reference group).
a
Reference level.
BRFSS, Behavioral Risk Factor Surveillance System.
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